ANEBULO PHARMACEUTICALS INC (ANEB)

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Monday Sector Laggards: Drugs, Biotechnology Stocks

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Lifecore Biomedical Announces Cooperation Agreement with 22NW

Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board

ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024

ANEB stock results show that Anebulo Pharmaceuticals beat analyst estimates for earnings per share the third quarter of 2024.

ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Anebulo Pharmaceuticals (NASDAQ:ANEB) just reported results for the third quart...

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Anebulo Pharmaceuticals Announces New CEO

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel...

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates